Educational use only
Immune-system claims can affect medical decisions. This page does not recommend Thymalin, Thymogen, or any thymus peptide for infection, cancer, immune deficiency, aging, or prevention.
Identity snapshot
| Thymalin / Timalin | Thymus-derived peptide complex from Russian/USSR clinical literature. |
|---|---|
| Thymogen / Timogen | Synthetic short peptide listed as EW - Glu-Trp. |
| Khavinson table activity | Thymogen is listed as an immunomodulator. |
| Product-family overlap | Vladonix is usually the Cytomax thymus-complex name; Thymogen is also encountered as a clinical and synthetic term. |
Common confusions
- Thymalin is not a single EW sequence.
It is described as a polypeptide or peptide complex from thymus tissue. - Thymogen is not thymosin alpha-1.
Both are thymus-related names, but they are different molecules and research traditions. - Thymalin is not thymulin.
Thymulin is a separate thymic hormone term and should not be folded into this catalog entry. - Russian clinical use is not U.S. approval.
Country, product, route, formulation, and manufacturer matter.
Evidence map
Thymalin has older Russian-language human literature and later mechanism-focused work. PubMed-indexed entries include studies on immunologic reactivity in non-specific lung diseases and a 2020 paper on hematopoietic stem-cell differentiation markers. These are not substitutes for modern independent clinical trials for a specific marketed product.
Thymogen's cleaner identity is the EW dipeptide. The 2014 Khavinson table lists it as an immunomodulator, but the table itself is an identity and activity source rather than a modern regulatory approval.
Thymalin benefits from studies, dosage from studies, and side effects
Search demand around Thymalin usually asks for immune benefits, anti-aging use, Thymalin dosage, side effects, FDA status, and legal status. This page does not provide protocols. Dosing language is limited to what an academic abstract or paper says about a specific study setting.
| Source context | Study-only dose or exposure | Reported endpoint | Interpretation limit |
|---|---|---|---|
| 1989 Russian lung-disease study abstract | The abstract reports only a 5 ml preparation volume and 4-6 injections per course, added to standard treatment; route and concentration are not stated in the accessible abstract. | Cellular-immunity markers and disease-course observations in 35 patients. | Historical, condition-specific abstract; not a general Thymalin dosage. |
| 2020 hematopoietic stem-cell paper | The accessible abstract and publisher preview do not state a dose or exposure concentration; they describe human umbilical-cord-blood HSC marker changes. | CD44/CD117 reduction and CD28 increase in stem-cell differentiation markers. | Mechanism-oriented evidence, not proof of broad immune benefits. |
| 2014 Khavinson short-peptide table | No Thymalin dose; identifies Thymogen as EW. | Thymogen listed as an immunomodulator. | Thymogen EW is not identical to Thymalin complex. |
Thymalin side effects: reported vs unknown
Some Khavinson-authored historical sources describe Thymalin as well tolerated, but that is not the same as modern systematic adverse-event evidence. Side-effect and safety claims depend on a specific product, route, manufacturer, country, and patient context. Older Russian clinical use and PubMed-indexed abstracts do not establish that an online Thymalin product is safe, legally marketed, sterile, or appropriate for immune-related self-treatment.
FDA status and legal status
Thymalin FDA status and Thymalin legal status searches need a specific product, country, route, and claim. This page does not identify an FDA-approved Thymalin drug in the United States as of the May 5, 2026 review. FDA approval, Russian clinical history, research-use labeling, and product catalog inclusion are separate claims that must be verified for a specific product and jurisdiction. FDA's 2024 US Chem Labs warning letter treated marketed "Thymalin" products with disease and structure/function claims as unapproved new drugs and misbranded drugs, noting that no approved applications were in effect for those products and that FDA had not evaluated them for safety, effectiveness, or quality. That is a legal-status warning for U.S. marketing claims, not a scientific verdict on every thymus-peptide paper.
Sources
- Khavinson, "Peptides, Genome, Aging" (2014) - Thymogen EW table entry.
- PubMed: Thymalin and hematopoietic stem cells.
- PMC entry: Thymalin and human hematopoietic stem cells - accessible abstract and article metadata.
- Springer preview: Thymalin and human hematopoietic stem cells - publisher abstract and DOI metadata.
- PubMed: Thymalin in non-specific lung disease literature.
- FDA: how to check whether a drug is approved - legal-status verification context.
- FDA warning letter involving marketed Thymalin products - U.S. legal-status context for claims.
- Khavinson and Morozov 2003 PDF - elderly cohort involving Thymalin and Epithalamin.